Heat Biologics Piotroski F Score
HTBX   USA Stock  USD 2.90 0.07 2.36% 
Heat Biologics Piotroski F Score  Heat Biologics Piotroski F Score 
At this time, it appears that Heat Biologics' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski FScore model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient longterm portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score  Frail
1  Current Return On Assets  Negative 
2  Change in Return on Assets  Decreased 
3  Cash Flow Return on Assets  Negative 
4  Current Quality of Earnings (accrual)  Improving 
5  Asset Turnover Growth  Increase 
6  Current Ratio Change  Increase 
7  Long Term Debt Over Assets Change  Higher Leverage 
8  Change In Outstending Shares  Increase 
9  Change in Gross Margin  No Change 
Heat Biologics Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Heat Biologics is to make sure Heat Biologics is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Heat Biologics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Heat Biologics' financial numbers are properly reported.
Current Value  Last Year  Change From Last Year  10 Year Trend  

Weighted Average Shares  19.8 M  18.4 M 

 
Weighted Average Shares Diluted  19.8 M  18.4 M 

 
Total Assets  154.1 M  142.8 M 

 
Total Liabilities  9.4 M  10 M 

 
Current Assets  141.2 M  130.9 M 

 
Current Liabilities  4.8 M  4.2 M 

 
Total Debt  2.8 M  2.1 M 

 
Gross Margin  0.89  0.9 

 
Asset Turnover  0.0401  0.0391 


Heat Biologics F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Heat Biologics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Heat Biologics in a muchoptimized way.
Click cells to compare fundamentals
About Heat Biologics Piotroski F Score
FScore is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his FScore binary model can help to predict the performance of low pricetobook stocks.Book Value per Share  6.72 
Heat Biologics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Heat Biologics from analyzing Heat Biologics' financial statements. These drivers represent accounts that assess Heat Biologics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Heat Biologics' important valuation drivers and their relationship over time.
2017  2018  2019  2020  2021  2022 (projected)  
Average Assets  16 M  31.75 M  28.5 M  87.47 M  100.59 M  108.53 M  
Earnings Before Interest Taxes and Depreciation Amortization EBITDA  (12.52 M)  (16.48 M)  (19.7 M)  (25.62 M)  (23.06 M)  (23.67 M)  
Earnings Before Interest Taxes and Depreciation Amortization USD  (12.52 M)  (16.48 M)  (19.7 M)  (25.62 M)  (23.06 M)  (23.67 M)  
Earnings before Tax  (12.65 M)  (16.72 M)  (19.97 M)  (26.05 M)  (23.44 M)  (24.06 M)  
Average Equity  9.41 M  22.51 M  19.78 M  78.13 M  89.85 M  96.94 M  
Enterprise Value  9.34 M  1.73 M  6.85 M  99.4 M  114.31 M  123.33 M  
Free Cash Flow  (6.46 M)  (22.31 M)  (12.99 M)  (22.36 M)  (20.12 M)  (21.71 M)  
Invested Capital  (2.17 M)  8.2 M  8.56 M  109.88 M  126.36 M  136.34 M  
Invested Capital Average  1.35 M  3.07 M  9.05 M  63.4 M  72.9 M  78.66 M  
Market Capitalization  13.7 M  22.79 M  16.22 M  122.4 M  140.76 M  151.87 M  
Tangible Asset Value  18 M  35.57 M  24.5 M  122.74 M  141.15 M  152.3 M  
Working Capital  1.41 M  23.84 M  6.77 M  110.14 M  126.66 M  136.66 M 
About Heat Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Heat Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Heat Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Heat Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patients immune system against cancer through Tcell activation and expansion. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina. Heat Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.
Heat Biologics Investors Sentiment
The influence of Heat Biologics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decisionmaking process regarding taking a position in Heat Biologics. The overall investor sentiment generally increases the direction of a stock movement in a oneyear investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.Heat Biologics Implied Volatility  1324.14 
Heat Biologics' implied volatility exposes the market's sentiment of Heat Biologics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Heat Biologics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Heat Biologics stock will not fluctuate a lot when Heat Biologics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Heat Biologics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Heat Biologics' short interest history, or implied volatility extrapolated from Heat Biologics options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Heat Biologics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Please check Heat Biologics Altman Z Score, Heat Biologics Correlation, Heat Biologics Valuation, as well as analyze Heat Biologics Alpha and Beta and Heat Biologics Hype Analysis. Note that the Heat Biologics information on this page should be used as a complementary analysis to other Heat Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Heat Biologics Stock analysis
When running Heat Biologics price analysis, check to measure Heat Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heat Biologics is operating at the current time. Most of Heat Biologics' value examination focuses on studying past and present price action to predict the probability of Heat Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Heat Biologics' price. Additionally, you may evaluate how the addition of Heat Biologics to your portfolios can decrease your overall portfolio volatility.
Performance AnalysisCheck effects of meanvariance optimization against your current asset allocation  Go  
Stock TickersUse highimpact, comprehensive, and customizable stock tickers that can be easily integrated to any websites  Go  
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing  Go  
Financial WidgetsEasily integrated Macroaxis content with over 30 different plugandplay financial widgets  Go  
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum  Go  
Idea BreakdownAnalyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sectorfocused investing themes  Go  
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets  Go  
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios  Go 
The market value of Heat Biologics is measured differently than its book value, which is the value of Heat Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of Heat Biologics' value that differs from its market value or its book value, called intrinsic value, which is Heat Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heat Biologics' market value can be influenced by many factors that don't directly affect Heat Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heat Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine Heat Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Heat Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.